Ⅰ. Notch信号通路基因在膀胱癌中的表达及预后分析研究 Ⅱ. 早期留置双J管在肾结核治疗中的临床应用研究
|
摘要
研究背景：
膀胱移行细胞癌(Transitional Cell Carcinoma of Bladder，TCCB)是泌尿系统最常见的肿瘤之一，是一多因素多阶段的发展过程，涉及抑癌基因的失活、癌基因的活化、细胞周期的调控、基因启动子的转录活化和表遗传学等诸多方面，而这些方面都与信号传导通路密切相关。Notch信号通路对肿瘤的发生发展具有广泛的多样化的影响，也是许多重要细胞信号通路的交汇点，以Notch为靶点的肿瘤基因治疗药物已被用于T细胞急性淋巴细胞白血病(T-cell acute lymphoblastic leukemias，T-ALL)的前期临床研究。然而Notch信号通路在TCCB发生发展中的作用并不明确。Notch信号通路是一条进化中高度保守的与细胞间通讯相关的通路，它在许多器官发育过程中起重要的作用，包括果蝇外周神经系统的发生、线虫的外阴发育和哺乳动物的淋巴系统发育。Notch信号转导通路由Notch受体、Notch配体和CSL(转录因子)三部分组成。人Notch受体家族包括4个成员(Notchl-4)和5种配体：Jagged1、Jagged2、Dll1、Dll3和Dll4。越来越多证据表明Notch信号通路与肿瘤发生发展有关，多数研究结果显示Notch具有促癌作用，但在皮肤癌和宫颈癌中为抑癌作用。
方法：
1．标本来源：收集本院2000至2008年膀胱移行细胞癌组织新鲜标本70例。其中男41例，女29例。年龄28～75岁，平均59岁。所有标本均经病理学检查诊断为膀胱移行细胞癌(TCCB)，并进行病理学分级及分期。病理分级按WHO标准，Ⅰ级35例，Ⅱ-Ⅲ级35例。临床分期按UICC-TNM标准，非浸润性膀胱癌(Ta)35例，浸润性膀胱癌(T1～T3)35例。另取10例正常膀胱黏膜作为对照组，剔除吸烟嗜酒者。一份标本留取后立即置于液氮中保存。另一份经10％甲醛溶液固定，常规石蜡包埋、切片，用于免疫组织化学染色。
2．采用免疫组化SP法定性检测Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1蛋白在70例膀胱移行细胞癌和10例正常膀胱粘膜组织中的表达情况。以在细胞质或细胞膜出现棕黄色颗粒为阳性，显微镜下观察并计数阳性染色细胞数。其表达以细胞染色的比率和强度进行判断：一为＜10％的细胞胞质或胞膜上微弱染色，+为11％-20％的细胞胞质或胞膜上中度或强染色，++为21-60％的细胞胞质或胞膜上强染色，+++为＞60％的细胞胞质或胞膜上强染色。
3．采用两步法RT-PCR检测Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1基因在mRNA水平的表达。
4．采用Western-Blot定量检测Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1基因在蛋白质水平的表达。
5．对70例患者进行随访分析，检测其肿瘤转移、复发时间及总生存时间，结合Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1基因的表达分析其与术后生存时间的关系。
结果
1．在10例正常膀胱移行上皮中以上5种Notch信号通路基因均为深染(+++)。非浸润性膀胱癌组织中染色主要集中于细胞膜上，染色较淡，浸润性膀胱癌中染色部位分布于细胞质中，呈片状浓聚。Notch信号通路基因分别根据其临床分期和病理分级，非浸润性膀胱癌和浸润性膀胱癌以及低级别和高级别膀胱癌的染色率有显著性差异(p＜0．05)。
2．通过RT-PCR检测正常膀胱移行上皮、非浸润性膀胱癌组织和浸润性膀胱癌组织中Notch信号通路各基因Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1的mRNA表达差异有统计学意义。
3．Western-Blot检测正常膀胱移行上皮、非浸润性膀胱癌组织和浸润性膀胱癌组织中Notch信号通路各基因Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1的蛋白质表达差异有统计学意义。
4．非浸润性膀胱癌患者的术后无瘤生存时间与Notch-1和Jagged-1基因的表达状态相关(p值分别为0．024和0．003)。结合不同Notch-1和Jagged-1基因的表达发现，两基因表达均较低者术后无瘤生存时间明显较短(28．09±8．84月)，而两基因表达均较高者术后无瘤生存时间明显较较长(88．78±6．81月)。四组患者术后无瘤生存时间差异有统计学意义(p=0．002)。
结论：
1．在正常膀胱粘膜上皮、非浸润性膀胱癌和浸润性膀胱癌中Notch信号通路基因的表达呈现3种模式。
2．非浸润性膀胱癌中Notch-1和Jagged-1基因的低表达与患者预后不良相关。
3．Notch信号通路在非浸润性膀胱癌中可能起抑癌基因的作用。
研究目的：
输尿管梗阻可加速肾结核的进展，而针对结核的抗痨治疗可促进输尿管的纤维化，使梗阻加重，最终导致肾功能严重损害。本课题拟明确早期留置输尿管双J管在肾结核治疗中的作用。
方法：
进行多中心随机临床病例研究，以比较单纯抗痨治疗和早期留置双J管对肾结核治疗的作用。随访时间至少为24个月，判断治疗失败的主要标准为患者患侧肾小球滤过率(GFR)降至10 ml／min。
结果：
共298名患者，被随机分配到单纯抗痨治疗和早期留置双J管组。随机分组24个月后，早期留置双J管组患者肾功能优于单纯抗痨组(p=0．012)，留置双J管组治疗失败的比例较低(p=0．001)。随机分组4周后，留置双J管组患者生活质量评分(Medical Outcomes Study 36-Item Short-Form General Health Survey questionnaire)也优于单纯抗痨治疗组(p=0．001)。
结论：
在肾结核患者中早期留置双J管，可有效保护肾功能，减少肾切除的可能性并提高生活质量。
Introduction: Bladder cancer is the 5th most common malignancy and the 4th leadingcause of cancer death of men in the United States. Clinically, the most important distinctionis that between papillary and invasive TCCB. Papillary cancers typically exhibit activationof the MAPK pathway, as a consequence of oncogenic mutations in FGFR3 or H-ras, withincreased Cyclin D1 expression. In the other way, invasive TCCB are characterized bysevere disturbances in proximate cell cycle regulators, e.g. Rb1 and CDKN2A/p16~(INK4A),which decrease dependency on mitogenic signaling. In addition, these disturbances permit,promote and are in turn exacerbated by chromosomal instability, which is further enhancedby loss of TP53 function. Intriguingly, neither canonical WNT/b-Cateninn nor hedgehogsignaling appear to play major roles in TCCB. This may reflect its origin from moredifferentiated urothelial cells possessing a high regenerative potential rather than a stem cellpopulation.Like urothelia, keratinocytes is not directly originated from stem cells and bothWNT and hedgehog signaling which have important crosstalk with Notch family are notactive. Notch factors in keratinocytes act as tumor suppressors, which is quite differentfrom other tumors. It inspired us to investigate the function of Notch family in TCCB.
Notch signaling participates in the development by maintaining the self-renewalpotential of some tissues and can positively or negatively influence proliferation,differentiation, and apoptosis depending on the cell types. To date, 4 Notch receptors havebeen identified (Notch 1-4) in humans, with corresponding ligands including Delta-like-1,Delta-like-3, Delta-like-4, Jagged-1 and Jagged-2. Involvement of Notch in cancer was firsthighlighted in human T-cell leukaemia, fuelling the notion that aberrant Notch signalingpromotes tumorigenesis. However, there is mounting evidence that Notch signaling is notexclusively oncogenic. It can instead function as a tumor suppressor in the skin. Theseapparently contradictory functions of Notch signaling strongly indicate that the outcome ofNotch activation is dependent on the cellular context.
To date, the Notch pathway has been rarely associated with TCCB. In this study, theexpression of Notch ligands and receptors was detected in normal and tumorous humanbladder transitional epithelia, respectively. The relationship between the expression patternof them and prognosis of bladder cancer patient was also evaluated.
MATERIALS AND METHODS: Patients and Tissue Samples: Fresh tumor tissuesnap-frozen in liquid nitrogen in the operating room was obtained from single hospitalbetween January 2000 and December 2006. All tumors were primary and diagnosedaccording to the WHO/ISUP classification of urothelial tumors and staged according to theTNM system as TaG1 in 35, T1G2 in 2, T2G2 in 16 and T3G3 in 17. These tissues werefrom 41 men and 29 women with the mean age at diagnosis being 59 years old (range 28 to75). None of them had received any preoperative therapy. For comparison, 10 cases ofnormal urothelia were obtained from surgical specimens. The pathological characteristics ofthese urothelia were confirmed by hematoxylin and eosin staining.
Immunohistochemical staining: Section preparation andimmunostaining were done aspreviously described. Two observers evaluated the staining pattern of the protein separatelyand scored each specimen for the percentage of positive cells identified. An average of 20fields was observed for each specimen. The immunoreactivity of a tissue sample wasconsidered negative (-) if less than 10% of the cells showed the same staining intensity asthe positive control in arterial endothelia, low expression level (+) if 11%-20% of the cellsshowed the staining above, medium expression level (++) if 21%-60% of the cells showedthe staining above and high expression level (+++) if more than 60% of the cells showedthe staining above.
Total RNA was extracted with TRIzol (Invitrogen) reagent. Two-step RT-PCR wascarried out in 25μl volume on indicated amounts of RNA by use of a gene specific primer.Western Blotting: Protein levels were determined by the Bradford assay. Protein extractswere mixed with SDS sample buffer and electrophoresed in 10%. The signals werevisualized with the ECL system (DuPont NEN, Wilmington DE, USA).
Statistical Analyses: The association between the expression of Notch factors intumors and the various clinicopathological variables was examined using the chi-square testor Fisher's exact test. Mann-Whitney U test was performed for continuous variables.Survival analyses were conducted according to the Kaplan-Meier method and survival characteristics were compared using log rank tests. Disease-flee survival was defined as theperiod between surgery and the detection of initial local recurrence, distant metastasis orstudy end. The Cox proportional hazards regression model was used to compare the relativeinfluences of different prognostic factors. The statistical software package SPSS 11.0 (SPSS,Inc., Chicago, Illinois) was used for all statistical analyses, with p＜0.05 indicatingstatistical significance.
RESULTS: In the present study tumors were divided into 2 groups of papillary (pTa)and invasive (pT1-pT3), respectively. All of the 5 kinds of Notch factors were intensivelystained in normal bladder transitional epithelia, but their expression was significantlydecreased in tumor tissues. Moreover, the expression level of the 5 proteins in the papillarytumors was lower than that in the invasive tumors (P＜0.05). In tumor cells, the immuneactivity of Notch factors was observed on the membranes of papillary tumor cells, while itbecame diffused and turned to cytoplasm in invasive ones. The expression of Notch factorswas not related with patients' age at diagnosis, sex, vascular invasion or lymph nodeinvolvement. No differences in immune activity of all the antibodies were found betweenthe basal cell layer and papillary layer of urothelia.
To further confirm the IHC results, the tissue samples were subjected to RT-PCR andWestern blot analysis. The papillary tumors showed weak immunoreactive bands of theexpected Notch factors molecular weight in western blot, whereas the normal and invasivetissues had intense expression. Among the three groups, each two of them had statisticaldifference.
Kaplan-Meier analyses revealed that the decreased expression of Notch-1 and Jagged-1was associated with an increased disease-free survival in papillary TCCB (p = 0.024 and0.003 respectively). Survival time of patients with low expression of both Notch-1 andJagged-1 was significantly shorter than that with other expression patterns in papillarytumors (p = 0.002). The expression pattern of other Notch factors was not correlated withthe survival time of the patients with invasive or all types of TCCB.
CONCLUSION: There are two expression patterns of Notch family in TCCB betweenpapillary and invasive tumors. The expression of Notch-1 and Jagged-1 is correlated withdisease-survival of papillary TCCB patients.
BACKGROUND: Tuberculous ureteral obstruction is a major cause of progressiveuropathy commonly complicates renal tuberculosis. The effect of chemotherapy andconcomitant fibrosis compounds the problem and results in renal loss. The possible benefitof early ureteral stenting in patients with renal tuberculosis is uncertain.
METHODS: We performed a multicenter, randomized clinical trial on patients withrenal tuberculosis comparing the efficacy of medication only with medication plus earlyureteral stenting. The lest follow-up period was 2 years. The primary outcome was the timeof glomerular filtration rate (GFR) reduced to 10 ml/min.
RESULTS: A total of 298 patients were randomly assigned to undergo either themedication only management or the early ureteral stenting procedure. The renal functioncould be better preserved by early ureteral stenting (P= 0.012). The rate of treatment failurewas lower in patients who underwent the early ureteral stenting procedure than in thosereceiving medication only (P= 0.001). After the first 4 week's of assignment, patientssubject to early ureteral stenting procedure had higher scores on the Medical OutcomesStudy 36-Item Short-Form General Health Survey questionnaire (P = 0.003).
CONCLUSIONS: Early ureteral stenting in patients with renal tuberculosis wasbeneficial to preservation of renal function, decreased the possibility of renal loss andimproved life quality.
膀胱移行细胞癌(Transitional Cell Carcinoma of Bladder，TCCB)是泌尿系统最常见的肿瘤之一，是一多因素多阶段的发展过程，涉及抑癌基因的失活、癌基因的活化、细胞周期的调控、基因启动子的转录活化和表遗传学等诸多方面，而这些方面都与信号传导通路密切相关。Notch信号通路对肿瘤的发生发展具有广泛的多样化的影响，也是许多重要细胞信号通路的交汇点，以Notch为靶点的肿瘤基因治疗药物已被用于T细胞急性淋巴细胞白血病(T-cell acute lymphoblastic leukemias，T-ALL)的前期临床研究。然而Notch信号通路在TCCB发生发展中的作用并不明确。Notch信号通路是一条进化中高度保守的与细胞间通讯相关的通路，它在许多器官发育过程中起重要的作用，包括果蝇外周神经系统的发生、线虫的外阴发育和哺乳动物的淋巴系统发育。Notch信号转导通路由Notch受体、Notch配体和CSL(转录因子)三部分组成。人Notch受体家族包括4个成员(Notchl-4)和5种配体：Jagged1、Jagged2、Dll1、Dll3和Dll4。越来越多证据表明Notch信号通路与肿瘤发生发展有关，多数研究结果显示Notch具有促癌作用，但在皮肤癌和宫颈癌中为抑癌作用。
方法：
1．标本来源：收集本院2000至2008年膀胱移行细胞癌组织新鲜标本70例。其中男41例，女29例。年龄28～75岁，平均59岁。所有标本均经病理学检查诊断为膀胱移行细胞癌(TCCB)，并进行病理学分级及分期。病理分级按WHO标准，Ⅰ级35例，Ⅱ-Ⅲ级35例。临床分期按UICC-TNM标准，非浸润性膀胱癌(Ta)35例，浸润性膀胱癌(T1～T3)35例。另取10例正常膀胱黏膜作为对照组，剔除吸烟嗜酒者。一份标本留取后立即置于液氮中保存。另一份经10％甲醛溶液固定，常规石蜡包埋、切片，用于免疫组织化学染色。
2．采用免疫组化SP法定性检测Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1蛋白在70例膀胱移行细胞癌和10例正常膀胱粘膜组织中的表达情况。以在细胞质或细胞膜出现棕黄色颗粒为阳性，显微镜下观察并计数阳性染色细胞数。其表达以细胞染色的比率和强度进行判断：一为＜10％的细胞胞质或胞膜上微弱染色，+为11％-20％的细胞胞质或胞膜上中度或强染色，++为21-60％的细胞胞质或胞膜上强染色，+++为＞60％的细胞胞质或胞膜上强染色。
3．采用两步法RT-PCR检测Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1基因在mRNA水平的表达。
4．采用Western-Blot定量检测Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1基因在蛋白质水平的表达。
5．对70例患者进行随访分析，检测其肿瘤转移、复发时间及总生存时间，结合Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1基因的表达分析其与术后生存时间的关系。
结果
1．在10例正常膀胱移行上皮中以上5种Notch信号通路基因均为深染(+++)。非浸润性膀胱癌组织中染色主要集中于细胞膜上，染色较淡，浸润性膀胱癌中染色部位分布于细胞质中，呈片状浓聚。Notch信号通路基因分别根据其临床分期和病理分级，非浸润性膀胱癌和浸润性膀胱癌以及低级别和高级别膀胱癌的染色率有显著性差异(p＜0．05)。
2．通过RT-PCR检测正常膀胱移行上皮、非浸润性膀胱癌组织和浸润性膀胱癌组织中Notch信号通路各基因Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1的mRNA表达差异有统计学意义。
3．Western-Blot检测正常膀胱移行上皮、非浸润性膀胱癌组织和浸润性膀胱癌组织中Notch信号通路各基因Notch-1、Notch-2、Notch-3、Jagged-1和DLL-1的蛋白质表达差异有统计学意义。
4．非浸润性膀胱癌患者的术后无瘤生存时间与Notch-1和Jagged-1基因的表达状态相关(p值分别为0．024和0．003)。结合不同Notch-1和Jagged-1基因的表达发现，两基因表达均较低者术后无瘤生存时间明显较短(28．09±8．84月)，而两基因表达均较高者术后无瘤生存时间明显较较长(88．78±6．81月)。四组患者术后无瘤生存时间差异有统计学意义(p=0．002)。
结论：
1．在正常膀胱粘膜上皮、非浸润性膀胱癌和浸润性膀胱癌中Notch信号通路基因的表达呈现3种模式。
2．非浸润性膀胱癌中Notch-1和Jagged-1基因的低表达与患者预后不良相关。
3．Notch信号通路在非浸润性膀胱癌中可能起抑癌基因的作用。
研究目的：
输尿管梗阻可加速肾结核的进展，而针对结核的抗痨治疗可促进输尿管的纤维化，使梗阻加重，最终导致肾功能严重损害。本课题拟明确早期留置输尿管双J管在肾结核治疗中的作用。
方法：
进行多中心随机临床病例研究，以比较单纯抗痨治疗和早期留置双J管对肾结核治疗的作用。随访时间至少为24个月，判断治疗失败的主要标准为患者患侧肾小球滤过率(GFR)降至10 ml／min。
结果：
共298名患者，被随机分配到单纯抗痨治疗和早期留置双J管组。随机分组24个月后，早期留置双J管组患者肾功能优于单纯抗痨组(p=0．012)，留置双J管组治疗失败的比例较低(p=0．001)。随机分组4周后，留置双J管组患者生活质量评分(Medical Outcomes Study 36-Item Short-Form General Health Survey questionnaire)也优于单纯抗痨治疗组(p=0．001)。
结论：
在肾结核患者中早期留置双J管，可有效保护肾功能，减少肾切除的可能性并提高生活质量。
Introduction: Bladder cancer is the 5th most common malignancy and the 4th leadingcause of cancer death of men in the United States. Clinically, the most important distinctionis that between papillary and invasive TCCB. Papillary cancers typically exhibit activationof the MAPK pathway, as a consequence of oncogenic mutations in FGFR3 or H-ras, withincreased Cyclin D1 expression. In the other way, invasive TCCB are characterized bysevere disturbances in proximate cell cycle regulators, e.g. Rb1 and CDKN2A/p16~(INK4A),which decrease dependency on mitogenic signaling. In addition, these disturbances permit,promote and are in turn exacerbated by chromosomal instability, which is further enhancedby loss of TP53 function. Intriguingly, neither canonical WNT/b-Cateninn nor hedgehogsignaling appear to play major roles in TCCB. This may reflect its origin from moredifferentiated urothelial cells possessing a high regenerative potential rather than a stem cellpopulation.Like urothelia, keratinocytes is not directly originated from stem cells and bothWNT and hedgehog signaling which have important crosstalk with Notch family are notactive. Notch factors in keratinocytes act as tumor suppressors, which is quite differentfrom other tumors. It inspired us to investigate the function of Notch family in TCCB.
Notch signaling participates in the development by maintaining the self-renewalpotential of some tissues and can positively or negatively influence proliferation,differentiation, and apoptosis depending on the cell types. To date, 4 Notch receptors havebeen identified (Notch 1-4) in humans, with corresponding ligands including Delta-like-1,Delta-like-3, Delta-like-4, Jagged-1 and Jagged-2. Involvement of Notch in cancer was firsthighlighted in human T-cell leukaemia, fuelling the notion that aberrant Notch signalingpromotes tumorigenesis. However, there is mounting evidence that Notch signaling is notexclusively oncogenic. It can instead function as a tumor suppressor in the skin. Theseapparently contradictory functions of Notch signaling strongly indicate that the outcome ofNotch activation is dependent on the cellular context.
To date, the Notch pathway has been rarely associated with TCCB. In this study, theexpression of Notch ligands and receptors was detected in normal and tumorous humanbladder transitional epithelia, respectively. The relationship between the expression patternof them and prognosis of bladder cancer patient was also evaluated.
MATERIALS AND METHODS: Patients and Tissue Samples: Fresh tumor tissuesnap-frozen in liquid nitrogen in the operating room was obtained from single hospitalbetween January 2000 and December 2006. All tumors were primary and diagnosedaccording to the WHO/ISUP classification of urothelial tumors and staged according to theTNM system as TaG1 in 35, T1G2 in 2, T2G2 in 16 and T3G3 in 17. These tissues werefrom 41 men and 29 women with the mean age at diagnosis being 59 years old (range 28 to75). None of them had received any preoperative therapy. For comparison, 10 cases ofnormal urothelia were obtained from surgical specimens. The pathological characteristics ofthese urothelia were confirmed by hematoxylin and eosin staining.
Immunohistochemical staining: Section preparation andimmunostaining were done aspreviously described. Two observers evaluated the staining pattern of the protein separatelyand scored each specimen for the percentage of positive cells identified. An average of 20fields was observed for each specimen. The immunoreactivity of a tissue sample wasconsidered negative (-) if less than 10% of the cells showed the same staining intensity asthe positive control in arterial endothelia, low expression level (+) if 11%-20% of the cellsshowed the staining above, medium expression level (++) if 21%-60% of the cells showedthe staining above and high expression level (+++) if more than 60% of the cells showedthe staining above.
Total RNA was extracted with TRIzol (Invitrogen) reagent. Two-step RT-PCR wascarried out in 25μl volume on indicated amounts of RNA by use of a gene specific primer.Western Blotting: Protein levels were determined by the Bradford assay. Protein extractswere mixed with SDS sample buffer and electrophoresed in 10%. The signals werevisualized with the ECL system (DuPont NEN, Wilmington DE, USA).
Statistical Analyses: The association between the expression of Notch factors intumors and the various clinicopathological variables was examined using the chi-square testor Fisher's exact test. Mann-Whitney U test was performed for continuous variables.Survival analyses were conducted according to the Kaplan-Meier method and survival characteristics were compared using log rank tests. Disease-flee survival was defined as theperiod between surgery and the detection of initial local recurrence, distant metastasis orstudy end. The Cox proportional hazards regression model was used to compare the relativeinfluences of different prognostic factors. The statistical software package SPSS 11.0 (SPSS,Inc., Chicago, Illinois) was used for all statistical analyses, with p＜0.05 indicatingstatistical significance.
RESULTS: In the present study tumors were divided into 2 groups of papillary (pTa)and invasive (pT1-pT3), respectively. All of the 5 kinds of Notch factors were intensivelystained in normal bladder transitional epithelia, but their expression was significantlydecreased in tumor tissues. Moreover, the expression level of the 5 proteins in the papillarytumors was lower than that in the invasive tumors (P＜0.05). In tumor cells, the immuneactivity of Notch factors was observed on the membranes of papillary tumor cells, while itbecame diffused and turned to cytoplasm in invasive ones. The expression of Notch factorswas not related with patients' age at diagnosis, sex, vascular invasion or lymph nodeinvolvement. No differences in immune activity of all the antibodies were found betweenthe basal cell layer and papillary layer of urothelia.
To further confirm the IHC results, the tissue samples were subjected to RT-PCR andWestern blot analysis. The papillary tumors showed weak immunoreactive bands of theexpected Notch factors molecular weight in western blot, whereas the normal and invasivetissues had intense expression. Among the three groups, each two of them had statisticaldifference.
Kaplan-Meier analyses revealed that the decreased expression of Notch-1 and Jagged-1was associated with an increased disease-free survival in papillary TCCB (p = 0.024 and0.003 respectively). Survival time of patients with low expression of both Notch-1 andJagged-1 was significantly shorter than that with other expression patterns in papillarytumors (p = 0.002). The expression pattern of other Notch factors was not correlated withthe survival time of the patients with invasive or all types of TCCB.
CONCLUSION: There are two expression patterns of Notch family in TCCB betweenpapillary and invasive tumors. The expression of Notch-1 and Jagged-1 is correlated withdisease-survival of papillary TCCB patients.
BACKGROUND: Tuberculous ureteral obstruction is a major cause of progressiveuropathy commonly complicates renal tuberculosis. The effect of chemotherapy andconcomitant fibrosis compounds the problem and results in renal loss. The possible benefitof early ureteral stenting in patients with renal tuberculosis is uncertain.
METHODS: We performed a multicenter, randomized clinical trial on patients withrenal tuberculosis comparing the efficacy of medication only with medication plus earlyureteral stenting. The lest follow-up period was 2 years. The primary outcome was the timeof glomerular filtration rate (GFR) reduced to 10 ml/min.
RESULTS: A total of 298 patients were randomly assigned to undergo either themedication only management or the early ureteral stenting procedure. The renal functioncould be better preserved by early ureteral stenting (P= 0.012). The rate of treatment failurewas lower in patients who underwent the early ureteral stenting procedure than in thosereceiving medication only (P= 0.001). After the first 4 week's of assignment, patientssubject to early ureteral stenting procedure had higher scores on the Medical OutcomesStudy 36-Item Short-Form General Health Survey questionnaire (P = 0.003).
CONCLUSIONS: Early ureteral stenting in patients with renal tuberculosis wasbeneficial to preservation of renal function, decreased the possibility of renal loss andimproved life quality.
引文
1. Sylvester, R. J.: [Natural history, recurrence, and progression in superficial bladder cancer. ScientificWorldJournal, 6: 2617,2006
2. Parekh, D. J., Bochner, B. H., Dalbagni, G: Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol, 24: 5519,2006
3. Zweidler-McKay, P. A.: Notch signaling in pediatric malignancies. Curr Oncol Rep, 10:459, 2008
4. Watt, F. M., Estrach, S., Ambler, C. A.: Epidermal Notch signalling: differentiation,cancer and adhesion. Curr Opin Cell Biol, 20:171, 2008
5. Zlotta, A. R., Schulman, C. C: Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am, 27:179, 2000
6. Bulbul, M. A., Husseini, N., Houjaij, A.: Superficial bladder cancer epidemiology,diagnosis and management. J Med Liban, 53: 107, 2005
7. Konety, B. R., Williams, R. D.: Superficial transitional (Ta/Tl/CIS) cell carcinoma of the bladder. BJU Int, 94: 18,2004
8. Dalbagni, G, Herr, H. W.: Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am, 27: 137, 2000
9. Talora, C, Campese, A.F., Bellavia, D., Felli, M. P., Vacca, A., Gulino, A., Screpanti, I.:Notch signaling and diseases: an evolutionary journey from a simple beginning to complex outcomes. Biochim Biophys Acta, 1782: 489, 2008
10. Poellinger, L., Lendahl, U.: Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr Opin Genet Dev, 18: 449, 2008
11. Schouwey, K., Beermann, F.: The Notch pathway: hair graying and pigment cell homeostasis. Histol Histopathol, 23: 609, 2008
12. Rizzo, P., Osipo, C, Foreman, K., Golde, T., Osborne, B., Miele, L.: Rational targeting of Notch signaling in cancer. Oncogene, 27: 5124, 2008
13. Okuyama, R., Tagami, H., Aiba, S.: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci, 49: 187, 2008
14. Nefedova, Y, Gabrilovich, D.: Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat, 11: 210, 2008
15. Maliekal, T. T., Bajaj, J., Giri, V., Subramanyam, D., Krishna, S.: The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene, 27: 5110,2008
16. Lukacs, N. W., Smit, J. J., Schaller, M. A., Lindell, D. M.: Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. Viral Immunol, 21:115, 2008
17. Leong, K. G, Gao, W. Q.: The Notch pathway in prostate development and cancer. Differentiation, 76: 699, 2008
18. Kovall, R. A.: More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene, 27: 5099, 2008
19. Karsan, A.: Notch and integrin affinity: a sticky situation. Sci Signal, 1: pe2, 2008
20. Jundt, E, Schwarzer, R., Dorken, B.: Notch signaling in leukemias and lymphomas. Curr Mol Med, 8: 51, 2008
21. Gordon, W. R., Arnett, K. L, Blacklow, S. C: The molecular logic of Notch signaling--a structural and biochemical perspective. J Cell Sci, 121: 3109, 2008
22. Gasperowicz, M., Otto, E: The notch signalling pathway in the development of the mouse placenta. Placenta, 29: 651, 2008
23. D'Souza, B., Miyamoto, A., Webmaster, G: The many facets of Notch ligands.Oncogene, 27: 5148, 2008
24. Dotto, G. P.: Notch tumor suppressor function. Oncogene, 27: 5115, 2008
25. Demarest, R. M., Ratti, E, Capobianco, A. J.: It's T-ALL about Notch. Oncogene, 27:5082, 2008
26.Aster, J. C, Pear, W. S., Blacklow, S. C: Notch signaling in leukemia. Annu Rev Pathol,3: 587, 2008
27. Wu, E, Stutzman, A., Mo, Y. Y: Notch signaling and its role in breast cancer. Front Biosci, 12: 4370, 2007
28. Stanley, P.: Regulation of Notch signaling by glycosylation. Curr Opin Struct Biol, 17:530, 2007
29. Shih Ie, M., Wang, T. L.: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res, 67: 1879, 2007
30. Roy, M., Pear, W. S., Aster, J. C: The multifaceted role of Notch in cancer. Curr Opin Genet Dev, 17: 52, 2007
31. Pinnix, C. C, Herlyn, M.: The many faces of Notch signaling in skin-derived cells.Pigment Cell Res, 20: 458, 2007
32. Nichols, J. T., Miyamoto, A., Weinmaster, G.: Notch signaling-constantly on the move.Traffic, 8: 959, 2007
33. Cheng, X., Huber, T. L, Chen, V. C, Gadue, P., Keller, G. M.: Numb mediates the interaction between Wnt and Notch to modulate primitive erythropoietic specification from the hemangioblast. Development, 135: 3447, 2008
34. Ishiyama, S., Matsueda, S., Jones, L. A., Efferson, C, Celestino, J., Schmandt, R.,Ioannides, C. G, Tsuda, N., Chang, D. Z.: Novel natural immunogenic peptides from Numbl and Notchl proteins for CD8+ cells in ovarian ascites. Int J Oncol, 30: 889,2007
35. Chapman, G, Liu, L., Sahlgren, C, Dahlqvist, C, Lendahl, U.: High levels of Notch signaling down-regulate Numb and Numblike. J Cell Biol, 175: 535, 2006
36. Nakamura, T, Tsuchiya, K., Watanabe, M.: Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol, 42: 705, 2007
37. Kunnimalaiyaan, M., Chen, H.: Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist, 12: 535, 2007
38. Koch, U., Radtke, R: Notch and cancer: a double-edged sword. Cell Mol Life Sci, 64:2746, 2007
39. Katoh, M.: Notch signaling in gastrointestinal tract (review). Int J Oncol, 30: 247, 2007
40. Katoh, M.: Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev, 3: 30, 2007
41. Hurlbut, G. D., Kankel, M. W., Lake, R. J., Artavanis-Tsakonas, S.: Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol, 19: 166, 2007
42. Yau, T., Chan, P., Epstein, R., Poon, R. T: Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int, 29: 10, 2009
43. Sanchez-Olea, R., Calera, M. R., Degterev, A.: Molecular pathways involved in cell death after chemically induced DNA damage. EXS, 99: 209, 2009
44. Hogberg, J., Silins, I., Stenius, U.: Chemical induced alterations in p53 signaling. EXS,99:181, 2009
45. Baud, V, Karin, M.: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov, 8: 33,2009
46. Zebedin, E., Freissmuth, M., Sexl, V: Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies? Leuk Lymphoma, 49: 620, 2008
47. Young, M. J.: Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens, 17:174, 2008
48. Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., Workman, P.: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol, 8: 393, 2008
49. Yan, Y, Merlin, D.: Ste20-related proline/alanine-rich kinase: a novel regulator of intestinal inflammation. World J Gastroenterol, 14: 6115, 2008
50. Xie, J.: Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai), 40: 670, 2008
51. Wong, H. H., Lemoine, N. R.: Biological approaches to therapy of pancreatic cancer. Pancreatology, 8: 431, 2008
52. Waugh, D. J., Wilson, C: The interleukin-8 pathway in cancer. Clin Cancer Res, 14:6735, 2008
53. Shi, W., Harris, A. L.: Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia, 11: 41, 2006
54. Sahlgren, C, Lendahl, U.: Notch signaling and its integration with other signaling mechanisms. Regen Med, 1:195, 2006
55. Chiba, S.: Notch signaling in stem cell systems. Stem Cells, 24: 2437, 2006
56. Miele, L., Miao, H., Nickoloff, B. J.: Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets, 6:313, 2006
57. Miele, L., Golde, T., Osborne, B.: Notch signaling in cancer. Curr Mol Med, 6: 905,2006
58. Miele, L: Notch signaling. Clin Cancer Res, 12:1074, 2006
59. Leong, K. G, Karsan, A.: Recent insights into the role of Notch signaling in tumorigenesis. Blood, 107: 2223, 2006
60. Hayward, S. D., Liu, J., Fujimuro, M.: Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci STKE, 2006: re4, 2006
61. Doroquez, D. B., Rebay, I.: Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit Rev Biochem Mol Biol, 41: 339,2006
62. Chiaramonte, R.: Still puzzling Notch signaling in B-cell malignancies. Leuk Res, 30:1331, 2006
63. Bray, S. J.: Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol, 7: 678, 2006
64. Bianchi, S., Dotti, M. T., Federico, A.: Physiology and pathology of notch signalling system. J Cell Physiol, 207: 300, 2006
65. Weng, A. P., Lau, A.: Notch signaling in T-cell acute lymphoblastic leukemia. Future Oncol, 1: 511, 2005
66. Sundaram, M. V: The love-hate relationship between Ras and Notch. Genes Dev, 19:1825, 2005
67. Sjolund, J., Manetopoulos, C, Stockhausen, M. T., Axelson, H.: The Notch pathway in cancer: differentiation gone awry. Eur J Cancer, 41: 2620, 2005
68. McKenzie, G. J., Khan, M., Briend, E., Stallwood, Y., Champion, B. R.: Notch: a unique therapeutic target for immunomodulation. Expert Opin Ther Targets, 9: 395, 2005
69. Li, J. L., Harris, A. L.: Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell, 8: 1, 2005
70. Lasky, J. L., Wu, H.: Notch signaling, brain development, and human disease. Pediatr Res, 57: 104R, 2005
71. Briend, E., Young, L. L., McKenzie, G. J., Tugal, T, Ragno, S., Champion, B. R.:Modulation of the notch pathway for immunotherapy. Curr Opin Mol Ther, 7: 56, 2005
72. Lundell, M. J., Lee, H. K., Perez, E., Chadwell, L.: The regulation of apoptosis by Numb/Notch signaling in the serotonin lineage of Drosophila. Development, 130: 4109, 2003
73. Givogri, M. I., Schonmann, V., Cole, R., De Vellis, J., Bongarzone, E. R.: Notchl and Numb genes are inversely expressed as oligodendrocytes differentiate. Dev Neurosci,25: 50, 2003
74. Weng, A. P., Aster, J. C: Multiple niches for Notch in cancer: context is everything.Curr Opin Genet Dev, 14: 48, 2004
75. Pahlman, S., Stockhausen, M. T., Fredlund, E., Axelson, H.: Notch signaling in neuroblastoma. Semin Cancer Biol, 14: 365, 2004
1. Maheshwari, P. N., Shah, H. N.: Nephrocutaneous fistula through percutaneous nephrolithotomy scar: rare presentation of genitourinary tuberculosis. Urology, 66: 655,2005
2. Cek, M., Lenk, S., Naber, K. G, Bishop, M. C, Johansen, T. E., Botto, H., Grabe, M.,Lobel, B., Redorta, J. P., Tenke, P.: EAU guidelines for the management of genitourinary tuberculosis. Eur Urol, 48: 353, 2005
3. Wang, L., Liu, J., Chin, D. P.: Progress in tuberculosis control and the evolving public-health system in China. Lancet, 369: 691, 2007
4. Madeb, R., Marshall, J., Nativ, O., Erturk, E.: Epididymal tuberculosis: case report and review of the literature. Urology, 65: 798, 2005
5. Zhang, X., Zheng, X, Ma, X., Li, H. Z., Li, L. C, Wang, S. G, Wu, Z. Q, Pan, T. J., Ye, Z. Q.: Comparison of retroperitoneoscopic nephrectomy versus open approaches to nonfunctioning tuberculous kidneys: a report of 44 cases. J Urol, 173: 1586, 2005
6. Xu, Z., Xin, M., Hong-Zhao, L., Zhong, C, Li, L. C, Ye, Z. Q.: Retroperitoneoscopic subcapsular nephrectomy for infective nonfunctioning kidney with dense perinephric adhesions. BJU Int, 94: 1329, 2004
7. Wang, L. J., Wu, C. K, Wong, Y. C, Chuang, C. K., Chu, S. H, Chen, C. J.: Imaging findings of urinary tuberculosis on excretory urography and computerized tomography.J Urol, 169: 524, 2003
8. Cahill, D., Dhanji, A., Williams, M., Smith, C, Montgomery, B.: Genitourinary tuberculosis in Middle England: look for it or miss it! BJU Int, 87: 273, 2001
9. New Classification of Physical Status. Anesthesiology, 24: 111, 1963
10. Lee, K. S., Kim, H. H., Byun, S. S., Kwak, C, Park, K., Ahn, H.: Laparoscopic nephrectomy for tuberculous nonfunctioning kidney: comparison with laparoscopic simple nephrectomy for other diseases. Urology, 60: 411, 2002
11. Hemal, A. K., Gupta, N. P., Kumar, R.: Comparison of retroperitoneoscopic nephrectomy with open surgery for tuberculous nonfunctioning kidneys. J Urol, 164: 32,2000
12. Khalaf, I. M., Shokeir, A. A., E1-Gyoushi, F. I., Amr, H. S., Amin, M. M.:Recoverability of renal function after treatment of adult patients with unilateral obstructive uropathy and normal contralateral kidney: a prospective study. Urology, 64: 664, 2004
13. Valles, P., Merlo, V., Beron, W., Manucha, W.: Recovery of distal nephron enzyme activity after release of unilateral ureteral obstruction. J Urol, 161: 641,1999
14. Weiss, S. G, 2nd, Kryger, J. V, Nakada, S. Y, Uehling, D. T.: Genitourinary tuberculosis. Urology, 51: 1033,1998
15. Waller, R. M., 3rd, Finnerty, D. P., Casarella, W. J.: Transluminal balloon dilation of a tuberculous ureteral stricture. J Urol, 129: 1225,1983
16. Murphy, D. M., Fallon, B., Lane, V, O'Flynn, J. D.: Tuberculous stricture of ureter.Urology, 20: 382,1982
17. Izes, J. K., Bihrle, W., 3rd, Thomas, C. B.: Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol, 150:1498,1993
18. DeHaven, J. I., Traynellis, C, Riggs, D. R., Ting, E., Lamm, D. L.: Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J Urol, 147: 738,1992
1 Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol,2002,20:395-425.
2 Gastpar R, Gehrmann M, Bausero MA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res, 2005,65:5238-47.
3 Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor,17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res, 2005,65:4929-38.
4 Beere HM, Green DR. Stress management - heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol, 2001,11:6-10.
5 Saleh A, Srinivasula SM, Balkir L, et al. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol, 2000,2:476-83.
6 Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90.EMBO J, 2000,19:4310-22.
7 Ravagnan L, Gurbuxani S, Susin SAl et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol, 2001,3:839-43.
8 Ran R, Zhou G, Lu A, et al. Hsp70 mutant proteins modulate additional apoptotic pathways and improve cell survival. Cell Stress Chaperones, 2004,9:229-42.
9 Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest, 2005,115:2633-9.
10 Meng X, Harken AH. The interaction between Hsp70 and TNF-alpha expression: a novel mechanism for protection of the myocardium against post-injury depression.Shock, 2002,17:345-53.
11 Zhao C, Wang E. Heat shock protein 90 suppresses tumor necrosis factor alpha induced apoptosis by preventing the cleavage of Bid in NIH3T3 fibroblasts. Cell Signal, 2004,16:313-21.
12 Rehman A, Chahal MS, Tang X, et al. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.Breast Cancer Res, 2005,7:R765-74.
13 Quenneville LA, Trotter MJ, Maeda T, et al. p53-dependent regulation of heat shock protein 72. Br J Dermatol, 2002,146:786-91.
14 Wang HH, Mao CY, Teng LS, et al. Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat Dis Int, 2006,5:22-7.
15 Yi H, Rong Y, Yankai Z, et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine, 2006.
16 Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res, 2005,11:8808-15.
17 Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous,tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother, 2005:1-11.
18 Brozovic A, Simaga S, Osmak M. Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia. Neoplasma, 2001,48:99-103.
19 Suriano R, Ghosh SK, Ashok BT, et al. Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention. Cancer Res,2005,65:6466-75.
20 Abe M, Manola JB, Oh WK, et al. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer,2004,3:49-53.
21 Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene, 2005,24:3328-38.
22 Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res,2000,60:7099-105.
23 Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res,2004,64:6595-602.
24 Lebret T, Watson RW, Molinie V, et al. Heat shock proteins HSP27, HSP60, HSP70,and HSP90: expression in bladder carcinoma. Cancer, 2003,98:970-7.
25 Storm FK, Mahvi DM, Gilchrist KW. Hsp-27 has no diagnostic or prognostic significance in prostate or bladder cancers. Urology, 1993,42:379-82.
26 Kamishima T, Fukuda T, Usuda H, et al. Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements. Pathol Int, 1997,47:166-73.
27 Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol,1997,109:157-65.
28 Roigas J, Wallen ES, Loening SA, et al. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Adv Exp Med Biol, 1998,451:225-9.
29 Sullivan CM, Smith DM, Matsui NM, et al. Identification of constitutive and gamma-interferon- and interleukin 4-regulated proteins in the human renal carcinoma cell line ACHN. Cancer Res, 1997,57:1137-43.
30 Tremolada L, Magni F, Valsecchi C, et al. Characterization of heat shock protein 27 phosphorylation sites in renal cell carcinoma. Proteomics, 2005,5:788-95.
31 Santarosa M, Favaro D, Quaia M, et al. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer,1997,33:873-7.
32 Suarez-Quian CA, Martinez-Garcia F, Nistal M, et al. Androgen receptor distribution in adult human testis. J Clin Endocrinol Metab, 1999,84:350-8.
33 Eddy EM. Role of heat shock protein HSP70-2 in spermatogenesis. Rev Reprod, 1999,4:23-30.
34 Richards EH, Hickman JA, Masters JR. Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br J Cancer,1995,72:620-6.
35 Richards EH, Hickey E, Weber L, et al. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res, 1996,56:2446-51.
36 Takashi M, Katsuno S, Sakata T, et al. Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues. Uro1 Res,1998,26:395-9.
37 de Wit NJ, Verschuure P, Kappe G, et al. Testis-specific human small heat shock protein HSPB9 is a cancer/testis antigen, and potentially interacts with the dynein subunit TCTEL1. Eur J Cell Biol, 2004,83:337-45.
1. Gupta, A., Watson, D. I.: Effect of laparoscopy on immune function. Br J Surg, 88:1296,2001
2. Romeo, C, Impellizzeri, P., Antonuccio, P., Turiaco, N., Cifala, S., Gentile, C,Passaniti, M., Marini, H., Squadrito, E, Altavilla, D.: Peritoneal macrophage activity after laparoscopy or laparotomy. J Pediatr Surg, 38: 97, 2003
3. Grande, M., Tucci, G R, Adorisio, O., Barini, A., Rulli, F., Neri, A., Franchi, F.,Farinon, A. M.: Systemic acute-phase response after laparoscopic and open cholecystectomy. Surg Endosc, 16: 313, 2002
4. Carter, J. J., Whelan, R. L.: The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am, 10: 655, 2001
5. Wildbrett, P., Oh, A., Naundorf, D., Volk, T., Jacobi, C. A.: Impact of laparoscopic gases on peritoneal microenvironment and essential parameters of cell function. Surg Endosc, 17: 78, 2003
6. Lewis, J. S., Lee, J. A., Underwood, J. C, Harris, A. L., Lewis, C. E.: Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol, 66: 889,1999
7. Murdoch, C, Giannoudis, A., Lewis, C. E.: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood, 104:2224, 2004
8. Jackson, P. G., Evans, S. R.: Intraperitoneal macrophages and tumor immunity: Areview. J Surg Oncol, 75: 146, 2000
9. Buunen, M., Gholghesaei, M., Veldkamp, R., Meijer, D. W., Bonjer, H. J., Bouvy, N.D.: Stress response to laparoscopic surgery, a review. Surg Endosc, 18:1022,2004
10. West, M. A., Baker, J., Bellingham, J.: Kinetics of decreased LPS-stimulated cytokine release by macrophages exposed to CO2. J Surg Res, 63: 269,1996
11. West, M. A., Hackam, D. J., Baker, J., Rodriguez, J. L., Bellingham, J., Rotstein, O.D.: Mechanism of decreased in vitro murine macrophage cytokine release after exposure to carbon dioxide: relevance to laparoscopic surgery. Ann Surg, 226: 179,1997
12. Kuntz, C, Wunsch, A., Bodeker, C, Bay, E, Rosch, R., Windeler, J., Herfarth, C:Effect of pressure and gas type on intraabdominal, subcutaneous, and blood pH in laparoscopy. Surg Endosc, 14: 367, 2000
13. Hajri, A., Mutter, D., Wack, S., Bastien, C, Gury, J. E, Marescaux, J., Aprahamian,M.: Dual effect of laparoscopy on cell-mediated immunity. Eur Surg Res, 32: 261,2000
14. Lee, S. W., Feingold, D. L., Carter, J. J., Zhai, C, Stapleton, G, Gleason, N., Whelan,R. L.: Peritoneal macrophage and blood monocyte functions after open and laparoscopic-assisted cecectomy in rats. Surg Endosc, 17: 1996, 2003
15. Fujii, K., Izumi, K., Sonoda, K., Shiraishi, N., Adachi, Y, Kitano, S.: Less impaired cell-mediated immune response in the murine peritoneal cavity after CO(2) pneumoperitoneum. Surg Today, 33: 833, 2003
16. Gutt, C. R, Hollander, D., Brier, C. H., Kim, Z. G, Lorenz, M.: Influence of laparoscopy and laparotomy on systemic and peritoneal T lymphocytes in a rat model. Int J Colorectal Dis, 16: 216, 2001
17. El-Hakim, A., Chiu, K. Y, Sherry, B., Bhuiya, T., Smith, A. D., Lee, B. R.: Peritoneal and systemic inflammatory mediators of laparoscopic bowel injury in a rabbit model.J Urol, 172: 1515, 2004
18. Aldana, J. P., Marcovich, R., Singhal, P., Reddy, K., Morgenstern, N., El-Hakim, A.,Smith, A. D., Lee, B. R.: Immune response to laparoscopic bowel injury. J Endourol,17: 317, 2003
19. Chekan, E. G, Nataraj, C, Clary, E. M., Hayward, T. Z., Brody, E J., Stamat, J. C,Fina, M. C, Eubanks, W. S., Westcott, C. J.: Intraperitoneal immunity and pneumoperitoneum. Surg Endosc, 13:1135,1999
20. Balague, C, Targarona, E. M., Pujol, M., Filella, X., Espert, J. J., Trias, M.: Peritoneal response to a septic challenge. Comparison between open laparotomy,pneumoperitoneum laparoscopy, and wall lift laparoscopy. Surg Endosc, 13: 792,1999
21. Clary, E. M., Bruch, S. M., Lau, C. L., Ali, A., Chekan, E. G, Garcia-Oria, M. J.,Eubanks, S.: Effects of pneumoperitoneum on hemodynamic and systemic immunologic responses to peritonitis in pigs. J Surg Res, 108: 32, 2002
22. Neuhaus, S. J., Watson, D. I., Ellis, T., Lafullarde, T., Jamieson, G. G., Russell, W. J.:Metabolic and immunologic consequences of laparoscopy with helium or carbon dioxide insufflation: a randomized clinical study. ANZ J Surg, 71: 447, 2001
23. Neuhaus, S. J., Watson, D. I., Ellis, T., Rofe, A. M., Mathew, G, Jamieson, G. G:Influence of gases on intraperitoneal immunity during laparoscopy in tumor-bearing rats. World J Surg, 24:1227, 2000
24. Kuntz, C, Wunsch, A., Rosch, R., Autschbach, R, Windeler, J., Herfarth, G: Short-and long-term results after laparoscopic vs conventional colon resection in a tumor-bearing small animal model. Surg Endosc, 14: 561,2000
25. Schietroma, M., Carlei, R, Franchi, L., Mazzotta, C, Sozio, A., Lygidakis, N. J., Amicucci, G: A comparison of serum interleukin-6 concentrations in patients treated by cholecystectomy via laparotomy or laparoscopy. Hepatogastroenterology, 51: 1595, 2004
26. Ohzato, H., Yoshizaki, K., Nishimoto, N., Ogata, A., Tagoh, H., Monden, M., Gotoh,M., Kishimoto, T., Mori, T.: Interleukin-6 as a new indicator of inflammatory status:detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery,111: 201,1992
27. Sietses, C, Havenith, C. E., Eijsbouts, Q. A., van Leeuwen, R A., Meijer, S., Beelen,R. H., Cuesta, M. A.: Laparoscopic surgery preserves monocyte-mediated tumor cell killing in contrast to the conventional approach. Surg Endosc, 14: 456, 2000
28. Liang, J. X, Shieh, M. J., Chen, C. N., Cheng, Y. M., Chang, K. J., Wang, S. M.:Prospective evaluation of laparoscopy-assisted colectomy versus laparotomy with resection for management of complex polyps of the sigmoid colon. World J Surg, 26:377, 2002
29. Landman, J., Olweny, E., Sundaram, C. P., Chen, C, Rehman, J., Lee, D. I., Shalhav,A., Portis, A., McDougall, E. M., dayman, R. V.: Prospective comparison of the immunological and stress response following laparoscopic and open surgery for localized renal cell carcinoma. J Urol,171: 1456, 2004
30. Kloosterman, T., von Blomberg, B. M., Borgstein, P., Cuesta, M. A., Scheper, R. J., Meijer, S.: Unimpaired immune functions after laparoscopic cholecystectomy.Surgery,115: 424,1994
31. Ordemann, J., Jacobi, C. A., Schwenk, W., Stosslein, R., Muller, J. M.: Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections. Surg Endosc, 15: 600, 2001
32. Leung, K. L, Tsang, K. S., Ng, M. H., Leung, K. J., Lai, P. B., Lee, J. R, Lau, W. Y:Lymphocyte subsets and natural killer cell cytotoxicity after laparoscopically assisted resection of rectosigmoid carcinoma. Surg Endosc, 17: 1305, 2003
33. Cams, M., Botchorishvili, R., Wattiez, A., Pouly, J. L., Mage, G, Manhes, H., Bruhat,M. A.: Cancer and laparoscopy, experimental studies: a review. Eur J Obstet Gynecol Reprod Biol, 91:1,2000
34. Concha, M. R., Mertz, V. E, Cortinez, L. I., Gonzalez, K. A., Butte, J. M., Lopez, E, Pinedo, G, Zuniga, A.: The volume of lactated Ringer's solution required to maintain preload and cardiac index during open and laparoscopic surgery. Anesth Analg,108:616, 2009
35. Sesay, M., Tauzin-Fin, P., Gosse, P., Ballanger, P., Maurette, P.: Real-time heart rate variability and its correlation with plasma catecholamines during laparoscopic adrenal pheochromocytoma surgery. Anesth Analg, 106:164, 2008
36. Lorenzo, A. J., Karsli, C, Halachmi, S., Dolci, M., Luginbuehl, I., Bissonnette, B., Farhat, W. A.: Hemodynamic and respiratory effects of pediatric urological retroperitoneal laparoscopic surgery: a prospective study. J Urol, 175: 1461, 2006
37. Suzuki, M., Koda, S., Nakamura, Y, Kawamura, N., Shimada, Y: The relationship between cardiac output measured by the thermodilution method and that measured by the carbon dioxide rebreathing technique during laparoscopic surgery. Anesth Analg,100:1381, 2005
38. Nadu, A., Ekstein, P., Szold, A., Friedman, A., Nakache, R., Cohen, Y, Matzkin, H.,Weinbroum, A. A.: Ventilatory and hemodynamic changes during retroperitoneal and transperitoneal laparoscopic nephrectomy: a prospective real-time comparison. J Urol,174: 1013, 2005
39. Artuso, D., Wayne, M., Cassaro, S., Cerabona, T., Teixeira, J., Grossi, R.: Hemodynamic changes during laparoscopic gastric bypass procedures. Arch Surg,140: 289, 2005
40. Alishahi, S.: Randomized clinical trial of the effect of pneumoperitoneum on cardiac function and haemodynamics during laparoscopic cholecystectomy (Br J Surg 2004; 91: 848-854). Br J Surg, 92: 378, 2005
41. Halachmi, S., El-Ghoneimi, A., Bissonnette, B., Zaarour, C, Bagli, D. J., McLorie, G.A., Khoury, A. E., Farhat, W.: Hemodynamic and respiratory effect of pediatric urological laparoscopic surgery: a retrospective study. J Urol, 170: 1651, 2003
42. Huettemann, E., Terborg, C, Sakka, S. G., Petrat, G., Schier, E, Reinhart, K.:Preserved CO(2) reactivity and increase in middle cerebral arterial blood flow velocity during laparoscopic surgery in children. Anesth Analg, 94: 255, 2002
43. Steinbrook, R. A., Bhavani-Shankar, K.: Hemodynamics during laparoscopic surgery in pregnancy. Anesth Analg, 93: 1570, 2001
44. Bohm, B., Rotting, N., Schwenk, W., Grebe, S., Mansmann, U.: A prospective randomized trial on heart rate variability of the surgical team during laparoscopic and conventional sigmoid resection. Arch Surg, 136: 305,2001
45. Alishahi, S., Francis, N., Crofts, S., Duncan, L., Bickel, A., Cuschieri, A.: Central and peripheral adverse hemodynamic changes during laparoscopic surgery and their reversal with a novel intermittent sequential pneumatic compression device. Ann Surg,233: 176, 2001
46. Maracaja-Neto, L. F., Vercosa, N., Roncally, A. C, Giannella, A., Bozza, F. A., Lessa,M. A.: Beneficial effects of high positive end-expiratory pressure in lung respiratory mechanics during laparoscopic surgery. Acta Anaesthesiol Scand, 53: 210, 2009 47. Salihoglu, Z., Demiroluk, S., Demirkiran, O., Cakmakkaya, S., Aydogan, R, Carkman, S., Kose, Y.: The effects of pneumothorax on the respiratory mechanics during laparoscopic surgery. J Laparoendosc Adv Surg Tech A, 18: 423, 2008
48. Nakamoto, M., Hirayama, H., Sato, Y., Konishi, K., Kakeji, Y, Hashizume, M.,Tamura, S.: Recovery of liver motion and deformation due to respiration using laparoscopic freehand 3D ultrasound system. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv, 9: 372, 2006
49. Bablekos, G. D., Michaelides, S. A., Roussou, T., Charalabopoulos, K. A.: Changes in breathing control and mechanics after laparoscopic vs open cholecystectomy. Arch Surg, 141:16, 2006
50. Sivaci, R., Orman, A., Yilmazer, M., Yilmaz, S., Ellidokuz, H., Polat, C: The effect of low-flow sevoflurane and desflurane on pulmonary mechanics during laparoscopic surgery. J Laparoendosc Adv Surg Tech A, 15: 125, 2005
51. Nguyen, N. T., Anderson, J. T., Budd, M., Fleming, N. W., Ho, H. S., Jahr, J., Stevens, C. M., Wolfe, B. M.: Effects of pneumoperitoneum on intraoperative pulmonary mechanics and gas exchange during laparoscopic gastric bypass. Surg Endosc, 18: 64,2004
52. Bannister, C. R, Brosius, K. K., Wulkan, M.: The effect of insufflation pressure on pulmonary mechanics in infants during laparoscopic surgical procedures. Paediatr Anaesth, 13: 785, 2003
53. Suter, M, Martinet, O.: Postoperative pulmonary dysfunction after bilateral inguinal hernia repair: a prospective randomized study comparing the Stoppa procedure with laparoscopic total extraperitoneal repair (TEPP). Surg Laparosc Endosc Percutan Tech,12: 420, 2002
54. Rizzotti, L., Vassiliou, M., Amygdalou, A., Psarakis, C, Rasmussen, T. R., Laopodis,V, Behrakis, P.: Respiratory system mechanics during laparoscopic cholecystectomy.Respir Med, 96: 268, 2002
55. Hasukic, S., Mesic, D.: Postoperative pulmonary changes after laparoscopic cholecystectomy. Med Arh, 55: 91, 2001
56. Castillo, O. A., Vitagliano, G: Port site metastasis and tumor seeding in oncologic laparoscopic urology. Urology, 71: 372,2008
57. Takeda, A., Mori, M., Sakai, K., Mitsui, T., Nakamura, H.: Parasitic peritoneal leiomyomatosis diagnosed 6 years after laparoscopic myomectomy with electric tissue morcellation: report of a case and review of the literature. J Minim Invasive Gynecol, 14: 770, 2007
58. Savage, S. J., Wingo, M. S., Hooper, H. B., Smith, M. T., Keane, T. E.: Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology, 70: 1222 e9, 2007
59. Permpongkosol, S., Chan, D. Y, Link, R. E., Jarrett, T. W., Kavoussi, L. R.:Laparoscopic radical nephrectomy: long-term outcomes. J Endourol, 19: 628, 2005
60. Lee, B. R., Tan, B. J., Smith, A. D.: Laparoscopic port site metastases: incidence, risk factors, and potential preventive measures. Urology, 65: 639, 2005
61. Ramirez, P. T., Frumovitz, M., Wolf, J. K., Levenback, C: Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer, 14:1070, 2004
62. Ramirez, P. T., Wolf, J. K., Levenback, C: Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol, 91:179, 2003
63. Picone, O., Aucouturier, J. S., Louboutin, A., Coscas, Y, Camus, E.: Abdominal wall metastasis of a cervical adenocarcinoma at the laparoscopic trocar insertion site after ovarian transposition: case report and review of the literature. Gynecol Oncol, 90: 446,2003
64. Ong, A. M., Bhayani, S. B., Pavlovich, C. P.: Trocar site recurrence after laparoscopic nephroureterectomy. J Urol,170: 1301, 2003
65. Zmora, O., Weiss, E. G: Trocar site recurrence in laparoscopic surgery for colorectal cancer. Myth or real concern? Surg Oncol Clin N Am, 10: 625, 2001
2. Parekh, D. J., Bochner, B. H., Dalbagni, G: Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol, 24: 5519,2006
3. Zweidler-McKay, P. A.: Notch signaling in pediatric malignancies. Curr Oncol Rep, 10:459, 2008
4. Watt, F. M., Estrach, S., Ambler, C. A.: Epidermal Notch signalling: differentiation,cancer and adhesion. Curr Opin Cell Biol, 20:171, 2008
5. Zlotta, A. R., Schulman, C. C: Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am, 27:179, 2000
6. Bulbul, M. A., Husseini, N., Houjaij, A.: Superficial bladder cancer epidemiology,diagnosis and management. J Med Liban, 53: 107, 2005
7. Konety, B. R., Williams, R. D.: Superficial transitional (Ta/Tl/CIS) cell carcinoma of the bladder. BJU Int, 94: 18,2004
8. Dalbagni, G, Herr, H. W.: Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am, 27: 137, 2000
9. Talora, C, Campese, A.F., Bellavia, D., Felli, M. P., Vacca, A., Gulino, A., Screpanti, I.:Notch signaling and diseases: an evolutionary journey from a simple beginning to complex outcomes. Biochim Biophys Acta, 1782: 489, 2008
10. Poellinger, L., Lendahl, U.: Modulating Notch signaling by pathway-intrinsic and pathway-extrinsic mechanisms. Curr Opin Genet Dev, 18: 449, 2008
11. Schouwey, K., Beermann, F.: The Notch pathway: hair graying and pigment cell homeostasis. Histol Histopathol, 23: 609, 2008
12. Rizzo, P., Osipo, C, Foreman, K., Golde, T., Osborne, B., Miele, L.: Rational targeting of Notch signaling in cancer. Oncogene, 27: 5124, 2008
13. Okuyama, R., Tagami, H., Aiba, S.: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci, 49: 187, 2008
14. Nefedova, Y, Gabrilovich, D.: Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies. Drug Resist Updat, 11: 210, 2008
15. Maliekal, T. T., Bajaj, J., Giri, V., Subramanyam, D., Krishna, S.: The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene, 27: 5110,2008
16. Lukacs, N. W., Smit, J. J., Schaller, M. A., Lindell, D. M.: Regulation of immunity to respiratory syncytial virus by dendritic cells, toll-like receptors, and notch. Viral Immunol, 21:115, 2008
17. Leong, K. G, Gao, W. Q.: The Notch pathway in prostate development and cancer. Differentiation, 76: 699, 2008
18. Kovall, R. A.: More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene, 27: 5099, 2008
19. Karsan, A.: Notch and integrin affinity: a sticky situation. Sci Signal, 1: pe2, 2008
20. Jundt, E, Schwarzer, R., Dorken, B.: Notch signaling in leukemias and lymphomas. Curr Mol Med, 8: 51, 2008
21. Gordon, W. R., Arnett, K. L, Blacklow, S. C: The molecular logic of Notch signaling--a structural and biochemical perspective. J Cell Sci, 121: 3109, 2008
22. Gasperowicz, M., Otto, E: The notch signalling pathway in the development of the mouse placenta. Placenta, 29: 651, 2008
23. D'Souza, B., Miyamoto, A., Webmaster, G: The many facets of Notch ligands.Oncogene, 27: 5148, 2008
24. Dotto, G. P.: Notch tumor suppressor function. Oncogene, 27: 5115, 2008
25. Demarest, R. M., Ratti, E, Capobianco, A. J.: It's T-ALL about Notch. Oncogene, 27:5082, 2008
26.Aster, J. C, Pear, W. S., Blacklow, S. C: Notch signaling in leukemia. Annu Rev Pathol,3: 587, 2008
27. Wu, E, Stutzman, A., Mo, Y. Y: Notch signaling and its role in breast cancer. Front Biosci, 12: 4370, 2007
28. Stanley, P.: Regulation of Notch signaling by glycosylation. Curr Opin Struct Biol, 17:530, 2007
29. Shih Ie, M., Wang, T. L.: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res, 67: 1879, 2007
30. Roy, M., Pear, W. S., Aster, J. C: The multifaceted role of Notch in cancer. Curr Opin Genet Dev, 17: 52, 2007
31. Pinnix, C. C, Herlyn, M.: The many faces of Notch signaling in skin-derived cells.Pigment Cell Res, 20: 458, 2007
32. Nichols, J. T., Miyamoto, A., Weinmaster, G.: Notch signaling-constantly on the move.Traffic, 8: 959, 2007
33. Cheng, X., Huber, T. L, Chen, V. C, Gadue, P., Keller, G. M.: Numb mediates the interaction between Wnt and Notch to modulate primitive erythropoietic specification from the hemangioblast. Development, 135: 3447, 2008
34. Ishiyama, S., Matsueda, S., Jones, L. A., Efferson, C, Celestino, J., Schmandt, R.,Ioannides, C. G, Tsuda, N., Chang, D. Z.: Novel natural immunogenic peptides from Numbl and Notchl proteins for CD8+ cells in ovarian ascites. Int J Oncol, 30: 889,2007
35. Chapman, G, Liu, L., Sahlgren, C, Dahlqvist, C, Lendahl, U.: High levels of Notch signaling down-regulate Numb and Numblike. J Cell Biol, 175: 535, 2006
36. Nakamura, T, Tsuchiya, K., Watanabe, M.: Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol, 42: 705, 2007
37. Kunnimalaiyaan, M., Chen, H.: Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist, 12: 535, 2007
38. Koch, U., Radtke, R: Notch and cancer: a double-edged sword. Cell Mol Life Sci, 64:2746, 2007
39. Katoh, M.: Notch signaling in gastrointestinal tract (review). Int J Oncol, 30: 247, 2007
40. Katoh, M.: Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev, 3: 30, 2007
41. Hurlbut, G. D., Kankel, M. W., Lake, R. J., Artavanis-Tsakonas, S.: Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol, 19: 166, 2007
42. Yau, T., Chan, P., Epstein, R., Poon, R. T: Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int, 29: 10, 2009
43. Sanchez-Olea, R., Calera, M. R., Degterev, A.: Molecular pathways involved in cell death after chemically induced DNA damage. EXS, 99: 209, 2009
44. Hogberg, J., Silins, I., Stenius, U.: Chemical induced alterations in p53 signaling. EXS,99:181, 2009
45. Baud, V, Karin, M.: Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov, 8: 33,2009
46. Zebedin, E., Freissmuth, M., Sexl, V: Signal interception-based therapies--a double-edged sword in Bcr/abl-induced malignancies? Leuk Lymphoma, 49: 620, 2008
47. Young, M. J.: Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens, 17:174, 2008
48. Yap, T. A., Garrett, M. D., Walton, M. I., Raynaud, F., de Bono, J. S., Workman, P.: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol, 8: 393, 2008
49. Yan, Y, Merlin, D.: Ste20-related proline/alanine-rich kinase: a novel regulator of intestinal inflammation. World J Gastroenterol, 14: 6115, 2008
50. Xie, J.: Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai), 40: 670, 2008
51. Wong, H. H., Lemoine, N. R.: Biological approaches to therapy of pancreatic cancer. Pancreatology, 8: 431, 2008
52. Waugh, D. J., Wilson, C: The interleukin-8 pathway in cancer. Clin Cancer Res, 14:6735, 2008
53. Shi, W., Harris, A. L.: Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia, 11: 41, 2006
54. Sahlgren, C, Lendahl, U.: Notch signaling and its integration with other signaling mechanisms. Regen Med, 1:195, 2006
55. Chiba, S.: Notch signaling in stem cell systems. Stem Cells, 24: 2437, 2006
56. Miele, L., Miao, H., Nickoloff, B. J.: Notch signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets, 6:313, 2006
57. Miele, L., Golde, T., Osborne, B.: Notch signaling in cancer. Curr Mol Med, 6: 905,2006
58. Miele, L: Notch signaling. Clin Cancer Res, 12:1074, 2006
59. Leong, K. G, Karsan, A.: Recent insights into the role of Notch signaling in tumorigenesis. Blood, 107: 2223, 2006
60. Hayward, S. D., Liu, J., Fujimuro, M.: Notch and Wnt signaling: mimicry and manipulation by gamma herpesviruses. Sci STKE, 2006: re4, 2006
61. Doroquez, D. B., Rebay, I.: Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit Rev Biochem Mol Biol, 41: 339,2006
62. Chiaramonte, R.: Still puzzling Notch signaling in B-cell malignancies. Leuk Res, 30:1331, 2006
63. Bray, S. J.: Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol, 7: 678, 2006
64. Bianchi, S., Dotti, M. T., Federico, A.: Physiology and pathology of notch signalling system. J Cell Physiol, 207: 300, 2006
65. Weng, A. P., Lau, A.: Notch signaling in T-cell acute lymphoblastic leukemia. Future Oncol, 1: 511, 2005
66. Sundaram, M. V: The love-hate relationship between Ras and Notch. Genes Dev, 19:1825, 2005
67. Sjolund, J., Manetopoulos, C, Stockhausen, M. T., Axelson, H.: The Notch pathway in cancer: differentiation gone awry. Eur J Cancer, 41: 2620, 2005
68. McKenzie, G. J., Khan, M., Briend, E., Stallwood, Y., Champion, B. R.: Notch: a unique therapeutic target for immunomodulation. Expert Opin Ther Targets, 9: 395, 2005
69. Li, J. L., Harris, A. L.: Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell, 8: 1, 2005
70. Lasky, J. L., Wu, H.: Notch signaling, brain development, and human disease. Pediatr Res, 57: 104R, 2005
71. Briend, E., Young, L. L., McKenzie, G. J., Tugal, T, Ragno, S., Champion, B. R.:Modulation of the notch pathway for immunotherapy. Curr Opin Mol Ther, 7: 56, 2005
72. Lundell, M. J., Lee, H. K., Perez, E., Chadwell, L.: The regulation of apoptosis by Numb/Notch signaling in the serotonin lineage of Drosophila. Development, 130: 4109, 2003
73. Givogri, M. I., Schonmann, V., Cole, R., De Vellis, J., Bongarzone, E. R.: Notchl and Numb genes are inversely expressed as oligodendrocytes differentiate. Dev Neurosci,25: 50, 2003
74. Weng, A. P., Aster, J. C: Multiple niches for Notch in cancer: context is everything.Curr Opin Genet Dev, 14: 48, 2004
75. Pahlman, S., Stockhausen, M. T., Fredlund, E., Axelson, H.: Notch signaling in neuroblastoma. Semin Cancer Biol, 14: 365, 2004
1. Maheshwari, P. N., Shah, H. N.: Nephrocutaneous fistula through percutaneous nephrolithotomy scar: rare presentation of genitourinary tuberculosis. Urology, 66: 655,2005
2. Cek, M., Lenk, S., Naber, K. G, Bishop, M. C, Johansen, T. E., Botto, H., Grabe, M.,Lobel, B., Redorta, J. P., Tenke, P.: EAU guidelines for the management of genitourinary tuberculosis. Eur Urol, 48: 353, 2005
3. Wang, L., Liu, J., Chin, D. P.: Progress in tuberculosis control and the evolving public-health system in China. Lancet, 369: 691, 2007
4. Madeb, R., Marshall, J., Nativ, O., Erturk, E.: Epididymal tuberculosis: case report and review of the literature. Urology, 65: 798, 2005
5. Zhang, X., Zheng, X, Ma, X., Li, H. Z., Li, L. C, Wang, S. G, Wu, Z. Q, Pan, T. J., Ye, Z. Q.: Comparison of retroperitoneoscopic nephrectomy versus open approaches to nonfunctioning tuberculous kidneys: a report of 44 cases. J Urol, 173: 1586, 2005
6. Xu, Z., Xin, M., Hong-Zhao, L., Zhong, C, Li, L. C, Ye, Z. Q.: Retroperitoneoscopic subcapsular nephrectomy for infective nonfunctioning kidney with dense perinephric adhesions. BJU Int, 94: 1329, 2004
7. Wang, L. J., Wu, C. K, Wong, Y. C, Chuang, C. K., Chu, S. H, Chen, C. J.: Imaging findings of urinary tuberculosis on excretory urography and computerized tomography.J Urol, 169: 524, 2003
8. Cahill, D., Dhanji, A., Williams, M., Smith, C, Montgomery, B.: Genitourinary tuberculosis in Middle England: look for it or miss it! BJU Int, 87: 273, 2001
9. New Classification of Physical Status. Anesthesiology, 24: 111, 1963
10. Lee, K. S., Kim, H. H., Byun, S. S., Kwak, C, Park, K., Ahn, H.: Laparoscopic nephrectomy for tuberculous nonfunctioning kidney: comparison with laparoscopic simple nephrectomy for other diseases. Urology, 60: 411, 2002
11. Hemal, A. K., Gupta, N. P., Kumar, R.: Comparison of retroperitoneoscopic nephrectomy with open surgery for tuberculous nonfunctioning kidneys. J Urol, 164: 32,2000
12. Khalaf, I. M., Shokeir, A. A., E1-Gyoushi, F. I., Amr, H. S., Amin, M. M.:Recoverability of renal function after treatment of adult patients with unilateral obstructive uropathy and normal contralateral kidney: a prospective study. Urology, 64: 664, 2004
13. Valles, P., Merlo, V., Beron, W., Manucha, W.: Recovery of distal nephron enzyme activity after release of unilateral ureteral obstruction. J Urol, 161: 641,1999
14. Weiss, S. G, 2nd, Kryger, J. V, Nakada, S. Y, Uehling, D. T.: Genitourinary tuberculosis. Urology, 51: 1033,1998
15. Waller, R. M., 3rd, Finnerty, D. P., Casarella, W. J.: Transluminal balloon dilation of a tuberculous ureteral stricture. J Urol, 129: 1225,1983
16. Murphy, D. M., Fallon, B., Lane, V, O'Flynn, J. D.: Tuberculous stricture of ureter.Urology, 20: 382,1982
17. Izes, J. K., Bihrle, W., 3rd, Thomas, C. B.: Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol, 150:1498,1993
18. DeHaven, J. I., Traynellis, C, Riggs, D. R., Ting, E., Lamm, D. L.: Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity. J Urol, 147: 738,1992
1 Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol,2002,20:395-425.
2 Gastpar R, Gehrmann M, Bausero MA, et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res, 2005,65:5238-47.
3 Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor,17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res, 2005,65:4929-38.
4 Beere HM, Green DR. Stress management - heat shock protein-70 and the regulation of apoptosis. Trends Cell Biol, 2001,11:6-10.
5 Saleh A, Srinivasula SM, Balkir L, et al. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol, 2000,2:476-83.
6 Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90.EMBO J, 2000,19:4310-22.
7 Ravagnan L, Gurbuxani S, Susin SAl et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol, 2001,3:839-43.
8 Ran R, Zhou G, Lu A, et al. Hsp70 mutant proteins modulate additional apoptotic pathways and improve cell survival. Cell Stress Chaperones, 2004,9:229-42.
9 Beere HM. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest, 2005,115:2633-9.
10 Meng X, Harken AH. The interaction between Hsp70 and TNF-alpha expression: a novel mechanism for protection of the myocardium against post-injury depression.Shock, 2002,17:345-53.
11 Zhao C, Wang E. Heat shock protein 90 suppresses tumor necrosis factor alpha induced apoptosis by preventing the cleavage of Bid in NIH3T3 fibroblasts. Cell Signal, 2004,16:313-21.
12 Rehman A, Chahal MS, Tang X, et al. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.Breast Cancer Res, 2005,7:R765-74.
13 Quenneville LA, Trotter MJ, Maeda T, et al. p53-dependent regulation of heat shock protein 72. Br J Dermatol, 2002,146:786-91.
14 Wang HH, Mao CY, Teng LS, et al. Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat Dis Int, 2006,5:22-7.
15 Yi H, Rong Y, Yankai Z, et al. Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65. Vaccine, 2006.
16 Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clin Cancer Res, 2005,11:8808-15.
17 Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous,tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother, 2005:1-11.
18 Brozovic A, Simaga S, Osmak M. Induction of heat shock protein 70 in drug-resistant cells by anticancer drugs and hyperthermia. Neoplasma, 2001,48:99-103.
19 Suriano R, Ghosh SK, Ashok BT, et al. Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention. Cancer Res,2005,65:6466-75.
20 Abe M, Manola JB, Oh WK, et al. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer,2004,3:49-53.
21 Gabai VL, Budagova KR, Sherman MY. Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene, 2005,24:3328-38.
22 Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res,2000,60:7099-105.
23 Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res,2004,64:6595-602.
24 Lebret T, Watson RW, Molinie V, et al. Heat shock proteins HSP27, HSP60, HSP70,and HSP90: expression in bladder carcinoma. Cancer, 2003,98:970-7.
25 Storm FK, Mahvi DM, Gilchrist KW. Hsp-27 has no diagnostic or prognostic significance in prostate or bladder cancers. Urology, 1993,42:379-82.
26 Kamishima T, Fukuda T, Usuda H, et al. Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements. Pathol Int, 1997,47:166-73.
27 Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol,1997,109:157-65.
28 Roigas J, Wallen ES, Loening SA, et al. Heat shock protein (HSP72) surface expression enhances the lysis of a human renal cell carcinoma by IL-2 stimulated NK cells. Adv Exp Med Biol, 1998,451:225-9.
29 Sullivan CM, Smith DM, Matsui NM, et al. Identification of constitutive and gamma-interferon- and interleukin 4-regulated proteins in the human renal carcinoma cell line ACHN. Cancer Res, 1997,57:1137-43.
30 Tremolada L, Magni F, Valsecchi C, et al. Characterization of heat shock protein 27 phosphorylation sites in renal cell carcinoma. Proteomics, 2005,5:788-95.
31 Santarosa M, Favaro D, Quaia M, et al. Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer,1997,33:873-7.
32 Suarez-Quian CA, Martinez-Garcia F, Nistal M, et al. Androgen receptor distribution in adult human testis. J Clin Endocrinol Metab, 1999,84:350-8.
33 Eddy EM. Role of heat shock protein HSP70-2 in spermatogenesis. Rev Reprod, 1999,4:23-30.
34 Richards EH, Hickman JA, Masters JR. Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br J Cancer,1995,72:620-6.
35 Richards EH, Hickey E, Weber L, et al. Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res, 1996,56:2446-51.
36 Takashi M, Katsuno S, Sakata T, et al. Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues. Uro1 Res,1998,26:395-9.
37 de Wit NJ, Verschuure P, Kappe G, et al. Testis-specific human small heat shock protein HSPB9 is a cancer/testis antigen, and potentially interacts with the dynein subunit TCTEL1. Eur J Cell Biol, 2004,83:337-45.
1. Gupta, A., Watson, D. I.: Effect of laparoscopy on immune function. Br J Surg, 88:1296,2001
2. Romeo, C, Impellizzeri, P., Antonuccio, P., Turiaco, N., Cifala, S., Gentile, C,Passaniti, M., Marini, H., Squadrito, E, Altavilla, D.: Peritoneal macrophage activity after laparoscopy or laparotomy. J Pediatr Surg, 38: 97, 2003
3. Grande, M., Tucci, G R, Adorisio, O., Barini, A., Rulli, F., Neri, A., Franchi, F.,Farinon, A. M.: Systemic acute-phase response after laparoscopic and open cholecystectomy. Surg Endosc, 16: 313, 2002
4. Carter, J. J., Whelan, R. L.: The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am, 10: 655, 2001
5. Wildbrett, P., Oh, A., Naundorf, D., Volk, T., Jacobi, C. A.: Impact of laparoscopic gases on peritoneal microenvironment and essential parameters of cell function. Surg Endosc, 17: 78, 2003
6. Lewis, J. S., Lee, J. A., Underwood, J. C, Harris, A. L., Lewis, C. E.: Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol, 66: 889,1999
7. Murdoch, C, Giannoudis, A., Lewis, C. E.: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood, 104:2224, 2004
8. Jackson, P. G., Evans, S. R.: Intraperitoneal macrophages and tumor immunity: Areview. J Surg Oncol, 75: 146, 2000
9. Buunen, M., Gholghesaei, M., Veldkamp, R., Meijer, D. W., Bonjer, H. J., Bouvy, N.D.: Stress response to laparoscopic surgery, a review. Surg Endosc, 18:1022,2004
10. West, M. A., Baker, J., Bellingham, J.: Kinetics of decreased LPS-stimulated cytokine release by macrophages exposed to CO2. J Surg Res, 63: 269,1996
11. West, M. A., Hackam, D. J., Baker, J., Rodriguez, J. L., Bellingham, J., Rotstein, O.D.: Mechanism of decreased in vitro murine macrophage cytokine release after exposure to carbon dioxide: relevance to laparoscopic surgery. Ann Surg, 226: 179,1997
12. Kuntz, C, Wunsch, A., Bodeker, C, Bay, E, Rosch, R., Windeler, J., Herfarth, C:Effect of pressure and gas type on intraabdominal, subcutaneous, and blood pH in laparoscopy. Surg Endosc, 14: 367, 2000
13. Hajri, A., Mutter, D., Wack, S., Bastien, C, Gury, J. E, Marescaux, J., Aprahamian,M.: Dual effect of laparoscopy on cell-mediated immunity. Eur Surg Res, 32: 261,2000
14. Lee, S. W., Feingold, D. L., Carter, J. J., Zhai, C, Stapleton, G, Gleason, N., Whelan,R. L.: Peritoneal macrophage and blood monocyte functions after open and laparoscopic-assisted cecectomy in rats. Surg Endosc, 17: 1996, 2003
15. Fujii, K., Izumi, K., Sonoda, K., Shiraishi, N., Adachi, Y, Kitano, S.: Less impaired cell-mediated immune response in the murine peritoneal cavity after CO(2) pneumoperitoneum. Surg Today, 33: 833, 2003
16. Gutt, C. R, Hollander, D., Brier, C. H., Kim, Z. G, Lorenz, M.: Influence of laparoscopy and laparotomy on systemic and peritoneal T lymphocytes in a rat model. Int J Colorectal Dis, 16: 216, 2001
17. El-Hakim, A., Chiu, K. Y, Sherry, B., Bhuiya, T., Smith, A. D., Lee, B. R.: Peritoneal and systemic inflammatory mediators of laparoscopic bowel injury in a rabbit model.J Urol, 172: 1515, 2004
18. Aldana, J. P., Marcovich, R., Singhal, P., Reddy, K., Morgenstern, N., El-Hakim, A.,Smith, A. D., Lee, B. R.: Immune response to laparoscopic bowel injury. J Endourol,17: 317, 2003
19. Chekan, E. G, Nataraj, C, Clary, E. M., Hayward, T. Z., Brody, E J., Stamat, J. C,Fina, M. C, Eubanks, W. S., Westcott, C. J.: Intraperitoneal immunity and pneumoperitoneum. Surg Endosc, 13:1135,1999
20. Balague, C, Targarona, E. M., Pujol, M., Filella, X., Espert, J. J., Trias, M.: Peritoneal response to a septic challenge. Comparison between open laparotomy,pneumoperitoneum laparoscopy, and wall lift laparoscopy. Surg Endosc, 13: 792,1999
21. Clary, E. M., Bruch, S. M., Lau, C. L., Ali, A., Chekan, E. G, Garcia-Oria, M. J.,Eubanks, S.: Effects of pneumoperitoneum on hemodynamic and systemic immunologic responses to peritonitis in pigs. J Surg Res, 108: 32, 2002
22. Neuhaus, S. J., Watson, D. I., Ellis, T., Lafullarde, T., Jamieson, G. G., Russell, W. J.:Metabolic and immunologic consequences of laparoscopy with helium or carbon dioxide insufflation: a randomized clinical study. ANZ J Surg, 71: 447, 2001
23. Neuhaus, S. J., Watson, D. I., Ellis, T., Rofe, A. M., Mathew, G, Jamieson, G. G:Influence of gases on intraperitoneal immunity during laparoscopy in tumor-bearing rats. World J Surg, 24:1227, 2000
24. Kuntz, C, Wunsch, A., Rosch, R., Autschbach, R, Windeler, J., Herfarth, G: Short-and long-term results after laparoscopic vs conventional colon resection in a tumor-bearing small animal model. Surg Endosc, 14: 561,2000
25. Schietroma, M., Carlei, R, Franchi, L., Mazzotta, C, Sozio, A., Lygidakis, N. J., Amicucci, G: A comparison of serum interleukin-6 concentrations in patients treated by cholecystectomy via laparotomy or laparoscopy. Hepatogastroenterology, 51: 1595, 2004
26. Ohzato, H., Yoshizaki, K., Nishimoto, N., Ogata, A., Tagoh, H., Monden, M., Gotoh,M., Kishimoto, T., Mori, T.: Interleukin-6 as a new indicator of inflammatory status:detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery,111: 201,1992
27. Sietses, C, Havenith, C. E., Eijsbouts, Q. A., van Leeuwen, R A., Meijer, S., Beelen,R. H., Cuesta, M. A.: Laparoscopic surgery preserves monocyte-mediated tumor cell killing in contrast to the conventional approach. Surg Endosc, 14: 456, 2000
28. Liang, J. X, Shieh, M. J., Chen, C. N., Cheng, Y. M., Chang, K. J., Wang, S. M.:Prospective evaluation of laparoscopy-assisted colectomy versus laparotomy with resection for management of complex polyps of the sigmoid colon. World J Surg, 26:377, 2002
29. Landman, J., Olweny, E., Sundaram, C. P., Chen, C, Rehman, J., Lee, D. I., Shalhav,A., Portis, A., McDougall, E. M., dayman, R. V.: Prospective comparison of the immunological and stress response following laparoscopic and open surgery for localized renal cell carcinoma. J Urol,171: 1456, 2004
30. Kloosterman, T., von Blomberg, B. M., Borgstein, P., Cuesta, M. A., Scheper, R. J., Meijer, S.: Unimpaired immune functions after laparoscopic cholecystectomy.Surgery,115: 424,1994
31. Ordemann, J., Jacobi, C. A., Schwenk, W., Stosslein, R., Muller, J. M.: Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections. Surg Endosc, 15: 600, 2001
32. Leung, K. L, Tsang, K. S., Ng, M. H., Leung, K. J., Lai, P. B., Lee, J. R, Lau, W. Y:Lymphocyte subsets and natural killer cell cytotoxicity after laparoscopically assisted resection of rectosigmoid carcinoma. Surg Endosc, 17: 1305, 2003
33. Cams, M., Botchorishvili, R., Wattiez, A., Pouly, J. L., Mage, G, Manhes, H., Bruhat,M. A.: Cancer and laparoscopy, experimental studies: a review. Eur J Obstet Gynecol Reprod Biol, 91:1,2000
34. Concha, M. R., Mertz, V. E, Cortinez, L. I., Gonzalez, K. A., Butte, J. M., Lopez, E, Pinedo, G, Zuniga, A.: The volume of lactated Ringer's solution required to maintain preload and cardiac index during open and laparoscopic surgery. Anesth Analg,108:616, 2009
35. Sesay, M., Tauzin-Fin, P., Gosse, P., Ballanger, P., Maurette, P.: Real-time heart rate variability and its correlation with plasma catecholamines during laparoscopic adrenal pheochromocytoma surgery. Anesth Analg, 106:164, 2008
36. Lorenzo, A. J., Karsli, C, Halachmi, S., Dolci, M., Luginbuehl, I., Bissonnette, B., Farhat, W. A.: Hemodynamic and respiratory effects of pediatric urological retroperitoneal laparoscopic surgery: a prospective study. J Urol, 175: 1461, 2006
37. Suzuki, M., Koda, S., Nakamura, Y, Kawamura, N., Shimada, Y: The relationship between cardiac output measured by the thermodilution method and that measured by the carbon dioxide rebreathing technique during laparoscopic surgery. Anesth Analg,100:1381, 2005
38. Nadu, A., Ekstein, P., Szold, A., Friedman, A., Nakache, R., Cohen, Y, Matzkin, H.,Weinbroum, A. A.: Ventilatory and hemodynamic changes during retroperitoneal and transperitoneal laparoscopic nephrectomy: a prospective real-time comparison. J Urol,174: 1013, 2005
39. Artuso, D., Wayne, M., Cassaro, S., Cerabona, T., Teixeira, J., Grossi, R.: Hemodynamic changes during laparoscopic gastric bypass procedures. Arch Surg,140: 289, 2005
40. Alishahi, S.: Randomized clinical trial of the effect of pneumoperitoneum on cardiac function and haemodynamics during laparoscopic cholecystectomy (Br J Surg 2004; 91: 848-854). Br J Surg, 92: 378, 2005
41. Halachmi, S., El-Ghoneimi, A., Bissonnette, B., Zaarour, C, Bagli, D. J., McLorie, G.A., Khoury, A. E., Farhat, W.: Hemodynamic and respiratory effect of pediatric urological laparoscopic surgery: a retrospective study. J Urol, 170: 1651, 2003
42. Huettemann, E., Terborg, C, Sakka, S. G., Petrat, G., Schier, E, Reinhart, K.:Preserved CO(2) reactivity and increase in middle cerebral arterial blood flow velocity during laparoscopic surgery in children. Anesth Analg, 94: 255, 2002
43. Steinbrook, R. A., Bhavani-Shankar, K.: Hemodynamics during laparoscopic surgery in pregnancy. Anesth Analg, 93: 1570, 2001
44. Bohm, B., Rotting, N., Schwenk, W., Grebe, S., Mansmann, U.: A prospective randomized trial on heart rate variability of the surgical team during laparoscopic and conventional sigmoid resection. Arch Surg, 136: 305,2001
45. Alishahi, S., Francis, N., Crofts, S., Duncan, L., Bickel, A., Cuschieri, A.: Central and peripheral adverse hemodynamic changes during laparoscopic surgery and their reversal with a novel intermittent sequential pneumatic compression device. Ann Surg,233: 176, 2001
46. Maracaja-Neto, L. F., Vercosa, N., Roncally, A. C, Giannella, A., Bozza, F. A., Lessa,M. A.: Beneficial effects of high positive end-expiratory pressure in lung respiratory mechanics during laparoscopic surgery. Acta Anaesthesiol Scand, 53: 210, 2009 47. Salihoglu, Z., Demiroluk, S., Demirkiran, O., Cakmakkaya, S., Aydogan, R, Carkman, S., Kose, Y.: The effects of pneumothorax on the respiratory mechanics during laparoscopic surgery. J Laparoendosc Adv Surg Tech A, 18: 423, 2008
48. Nakamoto, M., Hirayama, H., Sato, Y., Konishi, K., Kakeji, Y, Hashizume, M.,Tamura, S.: Recovery of liver motion and deformation due to respiration using laparoscopic freehand 3D ultrasound system. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv, 9: 372, 2006
49. Bablekos, G. D., Michaelides, S. A., Roussou, T., Charalabopoulos, K. A.: Changes in breathing control and mechanics after laparoscopic vs open cholecystectomy. Arch Surg, 141:16, 2006
50. Sivaci, R., Orman, A., Yilmazer, M., Yilmaz, S., Ellidokuz, H., Polat, C: The effect of low-flow sevoflurane and desflurane on pulmonary mechanics during laparoscopic surgery. J Laparoendosc Adv Surg Tech A, 15: 125, 2005
51. Nguyen, N. T., Anderson, J. T., Budd, M., Fleming, N. W., Ho, H. S., Jahr, J., Stevens, C. M., Wolfe, B. M.: Effects of pneumoperitoneum on intraoperative pulmonary mechanics and gas exchange during laparoscopic gastric bypass. Surg Endosc, 18: 64,2004
52. Bannister, C. R, Brosius, K. K., Wulkan, M.: The effect of insufflation pressure on pulmonary mechanics in infants during laparoscopic surgical procedures. Paediatr Anaesth, 13: 785, 2003
53. Suter, M, Martinet, O.: Postoperative pulmonary dysfunction after bilateral inguinal hernia repair: a prospective randomized study comparing the Stoppa procedure with laparoscopic total extraperitoneal repair (TEPP). Surg Laparosc Endosc Percutan Tech,12: 420, 2002
54. Rizzotti, L., Vassiliou, M., Amygdalou, A., Psarakis, C, Rasmussen, T. R., Laopodis,V, Behrakis, P.: Respiratory system mechanics during laparoscopic cholecystectomy.Respir Med, 96: 268, 2002
55. Hasukic, S., Mesic, D.: Postoperative pulmonary changes after laparoscopic cholecystectomy. Med Arh, 55: 91, 2001
56. Castillo, O. A., Vitagliano, G: Port site metastasis and tumor seeding in oncologic laparoscopic urology. Urology, 71: 372,2008
57. Takeda, A., Mori, M., Sakai, K., Mitsui, T., Nakamura, H.: Parasitic peritoneal leiomyomatosis diagnosed 6 years after laparoscopic myomectomy with electric tissue morcellation: report of a case and review of the literature. J Minim Invasive Gynecol, 14: 770, 2007
58. Savage, S. J., Wingo, M. S., Hooper, H. B., Smith, M. T., Keane, T. E.: Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review. Urology, 70: 1222 e9, 2007
59. Permpongkosol, S., Chan, D. Y, Link, R. E., Jarrett, T. W., Kavoussi, L. R.:Laparoscopic radical nephrectomy: long-term outcomes. J Endourol, 19: 628, 2005
60. Lee, B. R., Tan, B. J., Smith, A. D.: Laparoscopic port site metastases: incidence, risk factors, and potential preventive measures. Urology, 65: 639, 2005
61. Ramirez, P. T., Frumovitz, M., Wolf, J. K., Levenback, C: Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer, 14:1070, 2004
62. Ramirez, P. T., Wolf, J. K., Levenback, C: Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol, 91:179, 2003
63. Picone, O., Aucouturier, J. S., Louboutin, A., Coscas, Y, Camus, E.: Abdominal wall metastasis of a cervical adenocarcinoma at the laparoscopic trocar insertion site after ovarian transposition: case report and review of the literature. Gynecol Oncol, 90: 446,2003
64. Ong, A. M., Bhayani, S. B., Pavlovich, C. P.: Trocar site recurrence after laparoscopic nephroureterectomy. J Urol,170: 1301, 2003
65. Zmora, O., Weiss, E. G: Trocar site recurrence in laparoscopic surgery for colorectal cancer. Myth or real concern? Surg Oncol Clin N Am, 10: 625, 2001